Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

NCT01259856 is registered in ClinicalTrials.gov with Ronald Hoffman as lead sponsor.

NCT NCT01259856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01259856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Lead sponsor
Ronald Hoffman
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
June 30, 2017
Enrollment
168 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

high risk essential thrombocythemia, high risk polycythemia vera